Medicon Valley strikes back  

After a few slow years, the trust in the Øresund region as a force within biotechnology has returned.
Danish and Swedish companies located in the Øresund region are again attracting investor interest. The trust and cash flow in Medicon Valley has been rather limited the last two years. But recently the region has witnessed one large investment after the other and has thus in 2004 alone attracted more than DKK 2 billion. At the same time, the increasing number of investments in various biotech companies has strengthened the belief that the region may become one of the most interesting areas for biotechnology and Life Sciences in Europe.
As an example, Denmark’s largest biotech investor, Bankinvest, has attracted DKK 400 mill. out of a total of DKK 800 mill. to a new biotech fund – and there is a strong will to invest.
Medicon Valley is at present considered the third best biotech location in Europe.
The news was reported at

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×